Results 231 to 240 of about 2,875,336 (355)

Patient-reported outcome and experience measures in cardiovascular disease: a scoping review as part of iCARE4CVD. [PDF]

J Patient Rep Outcomes
Steiner B, Neumann A, Schwertfeger M, Verket M, Romero I, Hurtado C, Schiefel V, McNulty A, Sankarpandi S, Gingele AJ, Helms TM, Rocca HB, Zippel-Schultz B, iCARE4CVD consortium.   +13 more
europepmc   +1 more source

Clinical and patient reported outcomes using autologous fibrin sealant as adjunct to diode light amplification by stimulated emission of radiation‐assisted gingival depigmentation: A randomized controlled trial [PDF]

Duddukuri Murali Krishna, Sruthima NVS Gottumukkala, Gautami S Penmetsa, Konathala SV Ramesh, Pasupuleti Mohan Kumar, Manisha Beldhi   +5 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Assessing patient reported outcome measures: A practical guide for gastroenterologists [PDF]

, 2014
Bombardier C, Devlin NJ, Deyo RA, Domino G, Drossman DA, Masachs M, Mouzas IA, Muller S, Murphy KaCD, Nightingale F, Spaccavento S, Vandenberghe A, Verissimo R   +12 more
core   +1 more source

Efficacy and Patient-Reported Outcomes of a New Mometasone Cream Treating Atopic Eczema [PDF]

, 2012
Thomas Ruzicka, Christoph Willers, W. Wigger‐Alberti   +2 more
openalex   +1 more source

CORR Insights®: Is Shared Decision-making Associated with Better Patient-reported Outcomes? A Longitudinal Study of Patients Undergoing Total Joint Arthroplasty

, 2021
Nicole A. Wilson
openalex   +2 more sources

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

What patient reported outcome measures are used in clinical trials in hip fracture? A systematic mapping review. [PDF]

BMC Musculoskelet Disord
Yin R, Soh ZLH, Qin VM, Tasnim S, Rohr M, Apfelbacher C, Smith HE.   +6 more
europepmc   +1 more source

Community Health Worker and Mobile Health Programs to Help Young Adults with Sickle Cell Disease Transition to Using Adult Healthcare Services – the Comets Study; Results from Patient-Reported Outcomes at 6 Months [PDF]

Sophie Jan, Caren Steinway, Tanisha Belton, Justine Shults, Laura Bennett, Heather Griffis, Banu Aygün, Abena Appiah‐Kubi, Nataly Apollonsky, Donna Boruchov, Omar Niss, Lisa A. Schwartz, Lori E. Crosby, Lamia P. Barakat, Biree Andemariam, David M. Rubin, Kim Smith‐Whitley   +16 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source